about
Intravascular papillary endothelial hyperplasia: histomorphological and immunohistochemical features.Characterization and enzyme-conjugation of a specific anti-L1 nanobody.Angiogenic markers endoglin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine tumors.Angiogenesis and antiangiogenic agents in cervical cancer.Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy statusCorrelations between immune response and vascularization qRT-PCR gene expression clusters in squamous cervical cancer.Tumor neoangiogenesis detection by confocal laser endomicroscopy and anti-CD105 antibody: Pilot study.CD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma.Disruption and inactivation of the PP2A complex promotes the proliferation and angiogenesis of hemangioma endothelial cells through activating AKT and ERK.Breaking down the evidence for bevacizumab in advanced cervical cancer: past, present and future.Endoglin-targeted cancer therapy.Use of ribosome-inactivating proteins from Sambucus for the construction of immunotoxins and conjugates for cancer therapy.TGF-β and its coreceptors in cancerogenesis: an overview.Endoglin for tumor imaging and targeted cancer therapy.Elderberries: a source of ribosome-inactivating proteins with lectin activity.Transforming growth factor-beta1 induces microvascular abnormalities through a down-modulation of neural cell adhesion molecule in human hepatocellular carcinoma.Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer.Overexpression of endoglin (CD105) is associated with recurrence in radically resected gastric cancer.Endoglin - a marker of vascular endothelial cell proliferation in cancer.Modulatory Effects of Chemoradiation on Angiogenic Factors and Laminin in Cervical Cancer: Link with Treatment ResponseDifferent biomarkers in non-small cell lung cancer in blood vessel invasion.Prognostic value of microvessel density in cervical cancer
P2860
Q33590331-E9B77396-0799-42A1-92A1-2E40F3B8F408Q34410377-443C3DDA-F7B9-424E-BE5C-5F8EAB71EB1CQ34487201-5FA0993B-1F5E-439B-BEB6-32A94305A717Q34655335-508DC005-7291-4BA2-80DA-1E57D23E42FAQ34978084-6D4817C3-C3D0-45EA-9EEE-8AD618A39192Q35357735-511E75A3-E396-4906-BE7D-C3B7B390A04DQ35851032-52B55023-120A-433F-BB05-F7C0E281D3DEQ36041205-180CD2A3-C58B-4854-B423-093F702B74E4Q36413256-6AB0754F-F0B8-40D0-A3D0-F2BDDC84BAC9Q36937771-807FAF73-4ADA-4FEB-A3E9-96882BF8F555Q37804900-E8888BFE-0FE2-4731-9623-60798C0D1FBBQ37954333-971AFF41-CB3E-42C5-8E30-7F0986DFC730Q37959017-298E0C3D-1FFF-40EC-B74E-3CCC35AF2369Q38074721-7F48921F-27CF-4D1E-BE4E-227ADA0171D6Q38342640-CBF58E68-C4C3-4D0C-B9B6-C1F3113C3A2EQ39325325-E0701489-6198-49B8-9BA8-2CE120E1527BQ40068276-B613F08F-3D8C-4837-BBD8-EF2250E9F9D8Q41970114-E016F9D6-B19C-4350-993C-C387F5CDD84AQ43121223-17C3BD03-9D35-4C28-BBD2-3C987BD6D9C6Q49363771-10B462A4-F817-45E1-A260-61C71A453C50Q51725394-D2DEE55C-C978-4C7D-91F0-D9A51717EB5CQ57298075-F83C7D01-6A12-435A-86E2-F184A8F53AC8
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Expression of endoglin (CD105) in cervical cancer
@en
Expression of endoglin
@nl
type
label
Expression of endoglin (CD105) in cervical cancer
@en
Expression of endoglin
@nl
prefLabel
Expression of endoglin (CD105) in cervical cancer
@en
Expression of endoglin
@nl
P2093
P2860
P356
P1476
Expression of endoglin (CD105) in cervical cancer
@en
P2093
G G Kenter
G J Fleuren
H J Zijlmans
S Hazelbag
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605009
P407
P577
2009-04-07T00:00:00Z